References:
- Albers FC et al. Durability of clinical response following long-term treatment with mepolizumab in patients with severe eosinophilic asthma: the COLUMBA study. Poster presented at ATS 2018.
- Ortega H et al. Long-term safety of mepolizumab in patients with severe eosinophilic asthma: the COLUMBA study. Poster presented at ATS 2018.
- Ortega HG et al. N Engl J Med 2014; 371:1198–1207.
- Chupp GL et al. Lancet Respir Med 2017; 5:390–400.
- Lugogo N et al. Clin Ther 2016; 38:2058–2070.
- Bel EH et al. N Engl J Med 2014; 371;1189-1197.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.